RESUMO
Serum lysozyme activity has been determined in patients suffering from myeloproliferative diseases, chronic myelogenous leukaemia (CML), acute myelogenous leukaemia (AML), chronic lymphatic leukaemia (CLL) and pancytopenia (P). Lysozyme activity was tested in undiluted and tenfold diluted sera. Increased lysozyme activity was found in patients with CML and CLI, whereas there was no change in patients with AML and P. Dilution of sera enhanced lysozyme activity. These data may indicate the presence of inhibitor in the sera tested. The diagnostic significance of the presented findings is discussed.
Assuntos
Muramidase/sangue , Transtornos Mieloproliferativos/enzimologia , Humanos , Leucemia Linfoide/diagnóstico , Leucemia Linfoide/enzimologia , Leucemia Mieloide/diagnóstico , Leucemia Mieloide/enzimologia , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/enzimologia , Muramidase/antagonistas & inibidores , Pancitopenia/diagnóstico , Pancitopenia/enzimologiaRESUMO
The influence of stanozolol Stromba and phenformin Dibotin (Winthrop) and complamin (Wulfing) on transformation of 131J-fibrinogen administered intravenously was examined in 39 patients with arteriosclerosis obliterans. The patients were divided into 3 groups; one of the groups included untreated patients. Radioactivity of the plasma and of the urine was determined by means of a scintillation counter. The volume of plasma, plasma fibrinogen (g%, g, g/kg), half time of persistance (T 1/2) and degradation of fibrinogen were determined. The patients who received Dibotin and Stromba simultaneously showed statistically significant decrease of the plasma fibrinogen degradation im comparison to the control group. But in patients who received complamin in spite of significant decrease of the plasma fibrinogen (g%), the fibrinogen degradation was not different from the value obtained in the group.
Assuntos
Arteriosclerose/tratamento farmacológico , Fibrinólise/efeitos dos fármacos , Fenformin/uso terapêutico , Estanozolol/uso terapêutico , Adulto , Quimioterapia Combinada , Humanos , Iodo/metabolismo , Masculino , Pessoa de Meia-Idade , Niacinato de Xantinol/uso terapêuticoRESUMO
Kininogen level, that of active kinins and kininase activity in the plasma of patients suffering from cirrhosis of the liver and of healthy people were studied. The kininogen content was determined by different available methods i.e. the trypsin and acetone techniques and by means of the plasma and glandular kallikrein preparation. An increase in kininase activity and a lowered kininogen level as determined by all the methods were found in the sick persons. The maximal decrease in the kininogen level determined by means of the plasma kallikreins is substantiated in connection with the increased fibrinolytic activity of the plasma of the patients with hepatic cirrhosis.
